Showing results (1-10 of 63) with videos related to
Sort By:
Pageof 7
Epidemiologia E Prevenzione|April 1, 1997
[Hepatocellular carcinoma: a preventable cancer]S Viviani, A Jack, E Bah, et al.Journal of Biological Regulators and Homeostatic Agents|September 30, 1999
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?P Lissoni, F Brivio, S Viviani, et al.Seminars in Hematology|April 1, 1988
Treatment strategies for Hodgkin's diseaseG Bonadonna, A Santoro, S Viviani, et al.Seminars in Oncology|March 1, 1986
CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's diseaseA Santoro, S Viviani, P Valagussa, et al.Journal of Pineal Research|April 1, 1992
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patientsS Viviani, P Bidoli, S Spinazzé, et al.Seminars in Oncology|April 1, 1992
ABVD in the treatment of Hodgkin's diseaseV Bonfante, A Santoro, S Viviani, et al.Leukemia & Lymphoma|August 1, 1996
Vinorelbine: a new promising drug in Hodgkin's diseaseL Devizzi, A Santoro, V Bonfante, et al.Seminars in Oncology|March 1, 1985
Third-line salvage chemotherapy in Hodgkin's diseaseG Bonadonna, S Viviani, P Valagussa, et al.The International Journal of Biological Markers|October 1, 1989
Serum levels of interleukin-2 in cancer patients: preliminary considerationsP Lissoni, S Viviani, A Santoro, et al.Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement|January 1, 1984
Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimensG Bonadonna, A Santoro, S Viviani, et al.Pageof 7